Targeting the EGFRvIII-STAT5 axis with Src inhibition represents a specific clinically relevant vulnerability within this pathway and informs patient selection for precision medicine efforts to improve survival in glioblastoma. This evidence concerns the gene STAT5A and glioblastoma.